Analysts Set DRI Healthcare Trust (TSE:DHT.UN) Target Price at C$17.94

DRI Healthcare Trust (TSE:DHT.UN) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is C$17.94.

Several equities analysts recently issued reports on DHT.UN shares. CIBC lowered their price objective on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research report on Thursday, December 12th. National Bankshares lowered their price target on DRI Healthcare Trust from C$19.50 to C$17.50 and set an “outperform” rating on the stock in a report on Thursday, February 20th.

DRI Healthcare Trust Trading Down 1.1 %

TSE:DHT.UN opened at C$11.13 on Wednesday. The company’s 50 day moving average price is C$11.76 and its 200-day moving average price is C$12.45. DRI Healthcare Trust has a 52 week low of C$10.39 and a 52 week high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.